clinvestКачественная клиническая практикаKachestvennaya Klinicheskaya Praktika = Good Clinical Practice2588-05192618-8473ООО «Издательство ОКИ10.24411/2588-0519-2018-10051clinvest-417Research ArticleБЕЗОПАСНОСТЬ ЛЕКАРСТВDRUG SAFETYСовременные аспекты эпидемиологии врождённых аномалий развития: методологические вопросы и трансляция результатов исследований в клиническую практикуModern aspects of epidemiology of congenital anomalies of development: methodological issues and the translation of research fndings into clinical practicehttps://orcid.org/0000-0003-3107-7636РешетькоО. В.ReshetkoO. V.

Решетько Ольга Вилоровна, доктор медицинских наук, профессор, заведующая кафедрой фармакологии

Саратов

Reshetko Olga,  MD, professor, Head of Department of Pharmacology

Saratov

reshetko@yandex.ruЛуцевичК. А.LutsevichK. V.

Луцевич Константин Александрович, кандидат медицинских наук, доцент кафедры фармакологии

Саратов

Lutsevich Konstantin, PhD, Assistant Professor of Department of Pharmacology

Saratov

ФГБОУ ВО Саратовский ГМУ им. В.И. Разумовского Минздрава РоссииРоссияFSBEI HE V.I. Razumovsky Saratov SMU MOH RussiaRussian Federation201817012019035665Copyright © Решетько О.В., Луцевич К.А., 20192019Решетько О.В., Луцевич К.А.Reshetko O.V., Lutsevich K.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.clinvest.ru/jour/article/view/417

Достигнутые успехи в выявлении и характеристике факторов риска возникновения врождённых аномалий происходят в основном благодаря эпидемиологическим исследованиям, давшим многочисленные ассоциации между факторами риска и группами врождённых дефектов. Однако в клинической практике трансляция этих ассоциаций в качестве фактических причин остаётся весьма сложной. Характеристика и эпидемиологический анализ возможных факторов, в частности лекарственных средств, связанных с возникновением врождённых аномалий, имеют решающее значение для разработки профилактических мероприятий, оказывающих воздействие на распространённость дефектов. В дальнейшем уменьшению глобального бремени врождённых дефектов может способствовать интеграция исследований в области эпидемиологии, генетики и эпигенетики через персонализированные и популяционно ориентированные превентивные стратегии.

Progress achieved in the identifcation and characterization of the risk factors for congenital anomalies occur mainly from epidemiological studies, which gave many associations between risk factors and groups of birth defects. However, in clinical practice the transmission of these associations as the actual reasons remains very difcult. Characteristics and epidemiological analysis of possible factors, including drugs, associated with the occurrence of congenital anomalies, are crucial for the development of prevention activities that have an impact on the incidence of defects. To further reduce the global burden of birth defects can help the integration of studies in epidemiology, genetics and epigenetics through personalized and population oriented preventive strategies.

врождённые аномалииклассификацияметоды исследованияпричинно-следственная связьтератогеныфактор рискаэпидемиологияcausalitycase classificationcongenital anomaliesepidemiologyresearch methodsrisk factorteratogensReferenceswho.int [Internet]. World Health Organization. Congenital anomalies, Fact Sheet 370, World Health Organization, Geneva, Switzerland, 2016 [cited 2018 Aug 29]. Available from: http://www.who.int/mediacentre/factsheets/fs370/en/who.int [Internet]. World Health Organization. Congenital anomalies, Fact Sheet 370, World Health Organization, Geneva, Switzerland, 2016 [cited 2018 Aug 29]. Available from: http://www.who.int/mediacentre/factsheets/fs370/en/Christianson AL, Howson CP, Modell B. Te March of Dimes Global Report on Birth Defects: Te Hidden Toll of Dying and Disabled Children. New York: March of Dimes Birth Defects Foundation, White Plains, 2006.Christianson AL, Howson CP, Modell B. Te March of Dimes Global Report on Birth Defects: Te Hidden Toll of Dying and Disabled Children. New York: March of Dimes Birth Defects Foundation, White Plains, 2006.who.int [Internet]. World Health Assembly resolution 63.17: birth defects [updated May 21 2010; cited 2018 Aug 29]. Available from: http://apps.who.int/gb/ebwha/pdffiles/WHA63-REC1/WHA63REC1-P2-en.pdf.who.int [Internet]. World Health Assembly resolution 63.17: birth defects [updated May 21 2010; cited 2018 Aug 29]. Available from: http://apps.who.int/gb/ebwha/pdffiles/WHA63-REC1/WHA63REC1-P2-en.pdf.WHO/CDC/ICBDSR. Birth defects surveillance: a manual for programme managers [Internet]. Geneva: World Health Organization; 2014 [cited 2018 Aug 29]. Available from: http: //www.cdc.gov/ncbddd/birthdefectscount/documents/bd-surveillance-manual.pdf.WHO/CDC/ICBDSR. Birth defects surveillance: a manual for programme managers [Internet]. Geneva: World Health Organization; 2014 [cited 2018 Aug 29]. Available from: http: //www.cdc.gov/ncbddd/birthdefectscount/documents/bd-surveillance-manual.pdf.Feldkamp ML, Carey JC, Byrne JLB, et al. Etiology and clinical presentation of birth defects: population based study. BMJ. 2017;357:j2249. DOI: 10.1136/bmj.j2249Feldkamp ML, Carey JC, Byrne JLB, et al. Etiology and clinical presentation of birth defects: population based study. BMJ. 2017;357:j2249. DOI: 10.1136/bmj.j2249Goodrum LA, Hankins GDV, Jermain D, Chanaud CM. Conference report: complex clinical, legal, and ethical issues of pregnant and postpartum women as subjects in clinical trials. J Womens Health (Larchmt). 2003;12(9):857- 867. DOI: 10.1089/154099903770948087Goodrum LA, Hankins GDV, Jermain D, Chanaud CM. Conference report: complex clinical, legal, and ethical issues of pregnant and postpartum women as subjects in clinical trials. J Womens Health (Larchmt). 2003;12(9):857- 867. DOI: 10.1089/154099903770948087Wlodarczyk B, Palacios A, Chapa C, et al. Genetic basis of susceptibility to teratogen induced birth defects. Am J Med Genet C Semin Med Genet. 2011;157C (3):215-226. DOI: 10.1002/ajmg.c.30314Wlodarczyk B, Palacios A, Chapa C, et al. Genetic basis of susceptibility to teratogen induced birth defects. Am J Med Genet C Semin Med Genet. 2011;157C (3):215-226. DOI: 10.1002/ajmg.c.30314Rasmussen SA, Erickson JD, Reef SE, Ross DS. Teratology: from science to birth defects prevention. Birth Defects Res A Clin Mol Teratol. 2009;85(1):82- 92. DOI: 10.1002/bdra.20506Rasmussen SA, Erickson JD, Reef SE, Ross DS. Teratology: from science to birth defects prevention. Birth Defects Res A Clin Mol Teratol. 2009;85(1):82- 92. DOI: 10.1002/bdra.20506Hernandez-Diaz S, Oberg AS. Are epidemiological approaches suitable to study risk/preventive factors for human birth defects? Curr Epidemiol Rep. 2015;2(1):31-36. DOI: 10.1007/s40471-015-0037-5Hernandez-Diaz S, Oberg AS. Are epidemiological approaches suitable to study risk/preventive factors for human birth defects? Curr Epidemiol Rep. 2015;2(1):31-36. DOI: 10.1007/s40471-015-0037-5Friedman JM. Big risks in small groups: the difference between epidemiology and counselling. Birth Defects Res A Clin Mol Teratol. 2009;85(8):720-724. DOI: 10.1002/bdra.20606Friedman JM. Big risks in small groups: the difference between epidemiology and counselling. Birth Defects Res A Clin Mol Teratol. 2009;85(8):720-724. DOI: 10.1002/bdra.20606Feldkamp ML, Botto LD, Carey JC. Reflections on the etiology of structural birth defects: established teratogens and risk factors. Birth Defects Res A Clin Mol Teratol. 2015;103(8):652-655. DOI: 10.1002/bdra.23392Feldkamp ML, Botto LD, Carey JC. Reflections on the etiology of structural birth defects: established teratogens and risk factors. Birth Defects Res A Clin Mol Teratol. 2015;103(8):652-655. DOI: 10.1002/bdra.23392Rasmussen SA, Olney RS, Holmes LB, et al. Guidelines for case classifcation for the National Birth Defects Prevention Study. Birth Defects Res A Clin Mol Teratol. 2003;67(3):193-201. DOI: 10.1002/bdra.10012Rasmussen SA, Olney RS, Holmes LB, et al. Guidelines for case classifcation for the National Birth Defects Prevention Study. Birth Defects Res A Clin Mol Teratol. 2003;67(3):193-201. DOI: 10.1002/bdra.10012Holmes LB, Westgate MN. Inclusion and exclusion criteria for malformations in newborn infants exposed to potential teratogens. Birth Defects Res A Clin Mol Teratol. 2011;91(9):807-812. DOI: 10.1002/bdra.20842Holmes LB, Westgate MN. Inclusion and exclusion criteria for malformations in newborn infants exposed to potential teratogens. Birth Defects Res A Clin Mol Teratol. 2011;91(9):807-812. DOI: 10.1002/bdra.20842Lupo PJ, Symanski E, Waller DK, et al. Polytomous logistic regression as a tool for exploring heterogeneity across birth defect subtypes: an example using anencephaly and spina bifda. Birth Defects Res A Clin Mol Teratol. 2010;88(8):701-705. DOI: 10.1002/bdra.20671Lupo PJ, Symanski E, Waller DK, et al. Polytomous logistic regression as a tool for exploring heterogeneity across birth defect subtypes: an example using anencephaly and spina bifda. Birth Defects Res A Clin Mol Teratol. 2010;88(8):701-705. DOI: 10.1002/bdra.20671Botto LD, Lin AE, Riehle-Colarusso T, et al. Seeking causes: classifying and evaluating congenital heart defects in etiologic studies. Birth Defects Res A Clin Mol Teratol. 2007;79(10):714-727. DOI: 10.1002/bdra.20403Botto LD, Lin AE, Riehle-Colarusso T, et al. Seeking causes: classifying and evaluating congenital heart defects in etiologic studies. Birth Defects Res A Clin Mol Teratol. 2007;79(10):714-727. DOI: 10.1002/bdra.20403Correa A, Gilboa SM, Besser LM, et al. Diabetes mellitus and birth defects. Am J Obstet Gynecol. 2008;199 (3):237.e1—237.e9. DOI: 10.1016/j.ajog.2008.06.028Correa A, Gilboa SM, Besser LM, et al. Diabetes mellitus and birth defects. Am J Obstet Gynecol. 2008;199 (3):237.e1—237.e9. DOI: 10.1016/j.ajog.2008.06.028Khoury MJ. Commentary: contributions of epidemiology to the study of birth defects in humans. Teratology. 1995;52(4):186-189. DOI: 10.1002/tera.1420520403Khoury MJ. Commentary: contributions of epidemiology to the study of birth defects in humans. Teratology. 1995;52(4):186-189. DOI: 10.1002/tera.1420520403Jones KL, Jones MC, Del Campo M. (eds.) Smith’s recognizable patterns of human malformation. 7th ed. Saunders: 2013. 1019 p.Jones KL, Jones MC, Del Campo M. (eds.) Smith’s recognizable patterns of human malformation. 7th ed. Saunders: 2013. 1019 p.Solomon BD, Bear KA, Kimonis V, et al. Clinical geneticists’ views of VACTERL/VATER association. Am J Med Genet A. 2012;158A(12):3087-3100. DOI: 10.1002/ajmg.a.35638Solomon BD, Bear KA, Kimonis V, et al. Clinical geneticists’ views of VACTERL/VATER association. Am J Med Genet A. 2012;158A(12):3087-3100. DOI: 10.1002/ajmg.a.35638Perez-Aytes A, Ledo A, Boso V, et al. In utero exposure to mycophenolate mofetil: a characteristic phenotype? Am J Med Genet A. 2008;146A(1):1-7. DOI: 10.1002/ajmg.a.32117Perez-Aytes A, Ledo A, Boso V, et al. In utero exposure to mycophenolate mofetil: a characteristic phenotype? Am J Med Genet A. 2008;146A(1):1-7. DOI: 10.1002/ajmg.a.32117Tinker SC, Gilboa S, Reefuis J, et al. Challenges in studying modifable risk factors for birth defects. Curr Epidemiol Rep. 2015;2(1):23-30. DOI: 10.1007/s40471-014-0028-yTinker SC, Gilboa S, Reefuis J, et al. Challenges in studying modifable risk factors for birth defects. Curr Epidemiol Rep. 2015;2(1):23-30. DOI: 10.1007/s40471-014-0028-yScialli AR. Te National Birth Defects Prevention Study: how to communicate data. Semin Fetal Neonatal Med. 2014;19(3):170-176. DOI: 10.1016/j.siny.2013.09.007Scialli AR. Te National Birth Defects Prevention Study: how to communicate data. Semin Fetal Neonatal Med. 2014;19(3):170-176. DOI: 10.1016/j.siny.2013.09.007Howards PP, Johnson CY, Honein MA, Flanders WD. Adjusting for bias due to incomplete case ascertainment in case-control studies of birth defects. Am J Epidemiol. 2015;181(8):595-607. DOI: 10.1093/aje/kwu323Howards PP, Johnson CY, Honein MA, Flanders WD. Adjusting for bias due to incomplete case ascertainment in case-control studies of birth defects. Am J Epidemiol. 2015;181(8):595-607. DOI: 10.1093/aje/kwu323Kallen B. Te problem of confounding in studies of the effect of maternal drug use on pregnancy outcome. Obstet Gynecol Int. 2012;2012:148616. DOI: 10.1155/2012/148616Kallen B. Te problem of confounding in studies of the effect of maternal drug use on pregnancy outcome. Obstet Gynecol Int. 2012;2012:148616. DOI: 10.1155/2012/148616Werler MM. Congenital malformations and consequential epidemiology. Curr Epidemiol Rep. 2015;2(1):8-12. DOI: 10.1007/s40471-014-0029-xWerler MM. Congenital malformations and consequential epidemiology. Curr Epidemiol Rep. 2015;2(1):8-12. DOI: 10.1007/s40471-014-0029-xAgopian AJ, Lupo PJ, Tinker SC, et al. Working towards a risk prediction model for neural tube defects. Birth Defects Res A Clin Mol Teratol. 2012;94(3):141-146. DOI: 10.1002/bdra.22883Agopian AJ, Lupo PJ, Tinker SC, et al. Working towards a risk prediction model for neural tube defects. Birth Defects Res A Clin Mol Teratol. 2012;94(3):141-146. DOI: 10.1002/bdra.22883Agopian AJ, Tinker SC, Lupo PJ, et al. Proportion of neural tube defects attributable to known risk factors. Birth Defects Res A Clin Mol Teratol. 2013;97(1):42-46. DOI: 10.1002/bdra.23100Agopian AJ, Tinker SC, Lupo PJ, et al. Proportion of neural tube defects attributable to known risk factors. Birth Defects Res A Clin Mol Teratol. 2013;97(1):42-46. DOI: 10.1002/bdra.23100Yoon P, Rasmussen SA, Lynberg M, et al. Te National Birth Defects Prevention Study. Public Health Rep. 2001;116(Suppl 1):32-40. DOI: 10.1093/phr/116.S1.32Yoon P, Rasmussen SA, Lynberg M, et al. Te National Birth Defects Prevention Study. Public Health Rep. 2001;116(Suppl 1):32-40. DOI: 10.1093/phr/116.S1.32Rodriguez-Pinilla E, Mejias C, Prieto-Merino D, et al. Risk of hypospadias in newborn infants exposed to valproic acid during the frst trimester of pregnancy: a case-control study in Spain. Drug Saf. 2008;31(6):537- 543. DOI: 10.2165/00002018-200831060-00008Rodriguez-Pinilla E, Mejias C, Prieto-Merino D, et al. Risk of hypospadias in newborn infants exposed to valproic acid during the frst trimester of pregnancy: a case-control study in Spain. Drug Saf. 2008;31(6):537- 543. DOI: 10.2165/00002018-200831060-00008Werler MM, Louik C, Mitchell AA. Case-control studies for identifying novel teratogens. Am J Med Genet C Semin Med Genet. 2011;157C(3):201-208. DOI: 10.1002/ajmg.c.30307Werler MM, Louik C, Mitchell AA. Case-control studies for identifying novel teratogens. Am J Med Genet C Semin Med Genet. 2011;157C(3):201-208. DOI: 10.1002/ajmg.c.30307Poletta FA, Gili JA, Castilla EE. Latin American Collaborative Study of Congenital Malformations (ECLAMC): a model for health collaborative studies. Public Health Genomics. 2014;17(2):61-67. DOI: 10.1159/000356568Poletta FA, Gili JA, Castilla EE. Latin American Collaborative Study of Congenital Malformations (ECLAMC): a model for health collaborative studies. Public Health Genomics. 2014;17(2):61-67. DOI: 10.1159/000356568Hernán MA, Hernández-Díaz S, Werler MM, Mitchell AA. Causal knowledge as a prerequisite for confounding evaluation: an application to birth defects epidemiology. Am J Epidemiol. 2002;155(2):176-184. DOI: 10.1093/aje/155.2.176Hernán MA, Hernández-Díaz S, Werler MM, Mitchell AA. Causal knowledge as a prerequisite for confounding evaluation: an application to birth defects epidemiology. Am J Epidemiol. 2002;155(2):176-184. DOI: 10.1093/aje/155.2.176Wilcox AJ, Weinberg CR, Basso O. On the pitfalls of adjusting for gestational age at birth. Am J Epidemiol. 2011;174(9):1062-1068. DOI: 10.1093/aje/kwr230Wilcox AJ, Weinberg CR, Basso O. On the pitfalls of adjusting for gestational age at birth. Am J Epidemiol. 2011;174(9):1062-1068. DOI: 10.1093/aje/kwr230Holmes LB. Human teratogens: update 2010. Birth Defects Res A Clin Mol Teratol. 2011;91(1):1-7. DOI: 10.1002/bdra.20748Holmes LB. Human teratogens: update 2010. Birth Defects Res A Clin Mol Teratol. 2011;91(1):1-7. DOI: 10.1002/bdra.20748Obican S, Scialli AR. Teratogenic exposures. Am J Med Genet C Semin Med Genet. 2011;157C(3):150-169. DOI: 10.1002/ajmg.c.30310Obican S, Scialli AR. Teratogenic exposures. Am J Med Genet C Semin Med Genet. 2011;157C(3):150-169. DOI: 10.1002/ajmg.c.30310Simeone RM, Feldkamp ML, Reefuis J, et al. CDC Grand Rounds: understanding the causes of major birth defects — steps to prevention. MMWR Morb Mortal Wkly Rep. 2015;64(39):1104-1107. DOI: 10.15585/mmwr.mm6439a3Simeone RM, Feldkamp ML, Reefuis J, et al. CDC Grand Rounds: understanding the causes of major birth defects — steps to prevention. MMWR Morb Mortal Wkly Rep. 2015;64(39):1104-1107. DOI: 10.15585/mmwr.mm6439a3Srivastava D. Genetic regulation of cardiogenesis and congenital heart disease. Annu Rev Pathol. 2006;1:199-213. DOI: 10.1146/annurev.pathol.1.110304.100039Srivastava D. Genetic regulation of cardiogenesis and congenital heart disease. Annu Rev Pathol. 2006;1:199-213. DOI: 10.1146/annurev.pathol.1.110304.100039Zhu H, Kartiko S, Finnell RH. Importance of gene-environment interactions in the etiology of selected birth defects. Clin Genet. 2009;75(5):409- 423. DOI: 10.1111/j.1399-0004.2009.01174.xZhu H, Kartiko S, Finnell RH. Importance of gene-environment interactions in the etiology of selected birth defects. Clin Genet. 2009;75(5):409- 423. DOI: 10.1111/j.1399-0004.2009.01174.xFriedman JM. Using genomics for birth defects epidemiology: can epigenetics cut the GxE Gordian knot? Birth Defects Res A Clin Mol Teratol. 2011;91(12):986-989. DOI: 10.1002/bdra.22875Friedman JM. Using genomics for birth defects epidemiology: can epigenetics cut the GxE Gordian knot? Birth Defects Res A Clin Mol Teratol. 2011;91(12):986-989. DOI: 10.1002/bdra.22875Parker SE, Mai CT, Canfeld MA, et al. Updated National Birth Prevalence estimates for selected birth defects in the United States, 2004-2006. Birth Defects Res A Clin Mol Teratol. 2010;88(12):1008-1016. DOI: 10.1002/bdra.20735Parker SE, Mai CT, Canfeld MA, et al. Updated National Birth Prevalence estimates for selected birth defects in the United States, 2004-2006. Birth Defects Res A Clin Mol Teratol. 2010;88(12):1008-1016. DOI: 10.1002/bdra.20735Carmichael SL. Birth defects epidemiology. Eur J Med Genet. 2014;57(8):355-358. DOI: 10.1016/j.ejmg.2014.03.002.Carmichael SL. Birth defects epidemiology. Eur J Med Genet. 2014;57(8):355-358. DOI: 10.1016/j.ejmg.2014.03.002.Graham JM Jr, Hennekam RC. Genetics of common malformations. Eur J Med Genet. 2014;57(8):353-354. DOI: 10.1016/j.ejmg.2014.05.007Graham JM Jr, Hennekam RC. Genetics of common malformations. Eur J Med Genet. 2014;57(8):353-354. DOI: 10.1016/j.ejmg.2014.05.007Martínez-Frías ML. Talidomida: 50 an˜os despue´s [Te thalidomide experience: review of its effects 50 years later]. Med Clin (Barc). 2012;139(1):25- 32. DOI: 10.1016/j.medcli.2011.10.011. [Article in Spanish].Martínez-Frías ML. Talidomida: 50 an˜os despue´s [Te thalidomide experience: review of its effects 50 years later]. Med Clin (Barc). 2012;139(1):25- 32. DOI: 10.1016/j.medcli.2011.10.011. [Article in Spanish].Webber DM, MacLeod SL, Bamshad MJ, et al. Developments in our understanding of the genetic basis of birth defects. Birth Defects Res A Clin Mol Teratol. 2015;103(8):680-691. DOI: 10.1002/bdra.23385Webber DM, MacLeod SL, Bamshad MJ, et al. Developments in our understanding of the genetic basis of birth defects. Birth Defects Res A Clin Mol Teratol. 2015;103(8):680-691. DOI: 10.1002/bdra.23385Hobbs CA, Chowdhury S, Cleves MA, et al. Genetic epidemiology and nonsyndromic structural birth defects: from candidate genes to epigenetics. JAMA Pediatr. 2014;168(4):371-377. DOI: 10.1001/jamapediatrics.2013.4858Hobbs CA, Chowdhury S, Cleves MA, et al. Genetic epidemiology and nonsyndromic structural birth defects: from candidate genes to epigenetics. JAMA Pediatr. 2014;168(4):371-377. DOI: 10.1001/jamapediatrics.2013.4858Houk V, Oakley G Jr, Erickson JD, et al. Recommendations for the use of folic acid to reduce the number of cases of spina bifda and other neural tube defects. MMWR Recomm Rep. 1992;41(RR-14):1-7.Houk V, Oakley G Jr, Erickson JD, et al. Recommendations for the use of folic acid to reduce the number of cases of spina bifda and other neural tube defects. MMWR Recomm Rep. 1992;41(RR-14):1-7.Leslie EJ, Murray JC. Evaluating rare coding variants as contributing causes to non-syndromic clef lip and palate. Clin Genet. 2013;84(5):496-500. DOI: 10.1111/cge.12018Leslie EJ, Murray JC. Evaluating rare coding variants as contributing causes to non-syndromic clef lip and palate. Clin Genet. 2013;84(5):496-500. DOI: 10.1111/cge.12018Greene ND, Stanier P, Copp AJ. Genetics of human neural tube defects. Hum Mol Genet. 2009;18(R2):R113-129. DOI: 10.1093/hmg/ddp347Greene ND, Stanier P, Copp AJ. Genetics of human neural tube defects. Hum Mol Genet. 2009;18(R2):R113-129. DOI: 10.1093/hmg/ddp347Gelb B, Brueckner M, Chung W, et al. Te Congenital Heart Disease Genetic Network Study: rationale, design, and early results. Circ Res. 2013;112(4):698-706. DOI: 10.1161/CIRCRESAHA.111.300297Gelb B, Brueckner M, Chung W, et al. Te Congenital Heart Disease Genetic Network Study: rationale, design, and early results. Circ Res. 2013;112(4):698-706. DOI: 10.1161/CIRCRESAHA.111.300297Dixon MJ, Marazita ML, Beaty TH, Murray JC. Clef lip and palate: understanding genetic and environmental influences. Nat Rev Genet. 2011;12(3):167-178. DOI: 10.1038/nrg2933Dixon MJ, Marazita ML, Beaty TH, Murray JC. Clef lip and palate: understanding genetic and environmental influences. Nat Rev Genet. 2011;12(3):167-178. DOI: 10.1038/nrg2933Rana MS, Christoffels VM, Moorman AF. A molecular and genetic outline of cardiac morphogenesis. Acta Physiol (Oxf). 2013;207(4):588-615. DOI: 10.1111/apha.12061.Rana MS, Christoffels VM, Moorman AF. A molecular and genetic outline of cardiac morphogenesis. Acta Physiol (Oxf). 2013;207(4):588-615. DOI: 10.1111/apha.12061.Fahed AC, Gelb BD, Seidman JG, Seidman CE. Genetics of congenital heart disease: the glass half empty. Circ Res. 2013;112(4):707-720. DOI: 10.1161/CIRCRESAHA.112.300853Fahed AC, Gelb BD, Seidman JG, Seidman CE. Genetics of congenital heart disease: the glass half empty. Circ Res. 2013;112(4):707-720. DOI: 10.1161/CIRCRESAHA.112.300853Rosa FW. Teratogenicity of isotretinoin. Lancet. 1983;2(8348):513.Rosa FW. Teratogenicity of isotretinoin. Lancet. 1983;2(8348):513.van der Zanden LF, van Rooij IA, Feitz WF, et al. Common variants in DGKK are strongly associated with risk of hypospadias. Nat Genet. 2011;43(1):48-50. DOI: 10.1038/ng.721van der Zanden LF, van Rooij IA, Feitz WF, et al. Common variants in DGKK are strongly associated with risk of hypospadias. Nat Genet. 2011;43(1):48-50. DOI: 10.1038/ng.721Geller F, Feenstra B, Carstensen L, et al. Genome-wide association analyses identify variants in developmental genes associated with hypospadias. Nat Genet. 2014;46(9):957-963. DOI: 10.1038/ng.3063.Geller F, Feenstra B, Carstensen L, et al. Genome-wide association analyses identify variants in developmental genes associated with hypospadias. Nat Genet. 2014;46(9):957-963. DOI: 10.1038/ng.3063.Birnbaum S, Ludwig KU, Reutter H, et al. Key susceptibility locus for nonsyndromic clef lip with or without clef palate on chromosome 8q24. Nat Genet. 2009;41(4):473-477. DOI: 10.1038/ng.333Birnbaum S, Ludwig KU, Reutter H, et al. Key susceptibility locus for nonsyndromic clef lip with or without clef palate on chromosome 8q24. Nat Genet. 2009;41(4):473-477. DOI: 10.1038/ng.333Grant SF, Wang K, Zhang H, et al. A genome-wide association study identifes a locus for nonsyndromic clef lip with or without clef palate on 8q24. J Pediatr. 2009;155(6):909-913. DOI: 10.1016/j.jpeds.2009.06.020Grant SF, Wang K, Zhang H, et al. A genome-wide association study identifes a locus for nonsyndromic clef lip with or without clef palate on 8q24. J Pediatr. 2009;155(6):909-913. DOI: 10.1016/j.jpeds.2009.06.020Beaty TH, Ruczinski I, Murray JC, et al. Evidence for gene-environment interaction in a genome wide study of nonsyndromic clef palate. Genet Epidemiol. 2011;35(6):469-478. DOI: 10.1002/gepi.20595Beaty TH, Ruczinski I, Murray JC, et al. Evidence for gene-environment interaction in a genome wide study of nonsyndromic clef palate. Genet Epidemiol. 2011;35(6):469-478. DOI: 10.1002/gepi.20595Garcia-Barceló MM, Yeung MY, Miao XP, et al. Genome-wide association study identifes a susceptibility locus for biliary atresia on 10q24.2. Hum Mol Genet. 2010;19(14):2917-2925. DOI: 10.1093/hmg/ddq196Garcia-Barceló MM, Yeung MY, Miao XP, et al. Genome-wide association study identifes a susceptibility locus for biliary atresia on 10q24.2. Hum Mol Genet. 2010;19(14):2917-2925. DOI: 10.1093/hmg/ddq196Mangold E, Ludwig KU, Birnbaum S, et al. Genome-wide association study identifes two susceptibility loci for nonsyndromic clef lip with or without clef palate. Nat Genet. 2010;42(1):24-26. DOI: 10.1038/ng.506Mangold E, Ludwig KU, Birnbaum S, et al. Genome-wide association study identifes two susceptibility loci for nonsyndromic clef lip with or without clef palate. Nat Genet. 2010;42(1):24-26. DOI: 10.1038/ng.506Olshan AF, Hobbs CA, Shaw GM. Discovery of genetic susceptibility factors for human birth defects: an opportunity for a National Agenda. Am J Med Genet A. 2011;155A(8):1794-1797. DOI: 10.1002/ajmg.a.34103Olshan AF, Hobbs CA, Shaw GM. Discovery of genetic susceptibility factors for human birth defects: an opportunity for a National Agenda. Am J Med Genet A. 2011;155A(8):1794-1797. DOI: 10.1002/ajmg.a.34103Redon R, Ishikawa S, Fitch KR, et al. Global variation in copy number in the human genome. Nature. 2006;444(7118):444-454. DOI: 10.1038/nature05329Redon R, Ishikawa S, Fitch KR, et al. Global variation in copy number in the human genome. Nature. 2006;444(7118):444-454. DOI: 10.1038/nature05329Zhang F, Gu W, Hurles ME, Lupski JR. Copy number variation in human health, disease, and evolution. Annu Rev Genomics Hum Genet. 2009;10:451- 481. DOI: 10.1146/annurev.genom.9.081307.164217Zhang F, Gu W, Hurles ME, Lupski JR. Copy number variation in human health, disease, and evolution. Annu Rev Genomics Hum Genet. 2009;10:451- 481. DOI: 10.1146/annurev.genom.9.081307.164217Huisman SA, Redeker EJ, Maas SM, et al. High rate of mosaicism in individuals with Cornelia de Lange syndrome. J Med Genet. 2013;50(5):339- 344. DOI: 10.1136/jmedgenet-2012-101477Huisman SA, Redeker EJ, Maas SM, et al. High rate of mosaicism in individuals with Cornelia de Lange syndrome. J Med Genet. 2013;50(5):339- 344. DOI: 10.1136/jmedgenet-2012-101477Tapper WJ, Foulds N, Cross NC, et al. Megalencephaly syndromes: exome pipeline strategies for detecting low-level mosaic mutations. PLoS One. 2014;9(1):e86940. DOI: 10.1371/journal.pone.0086940Tapper WJ, Foulds N, Cross NC, et al. Megalencephaly syndromes: exome pipeline strategies for detecting low-level mosaic mutations. PLoS One. 2014;9(1):e86940. DOI: 10.1371/journal.pone.0086940Glidewell J, Reefuis J, Rasmu ssen SA, et al. Factors affecting maternal participation in the genetic component of the National Birth Defects Prevention Study — United States, 1997-2007. Genet Med. 2014;16(4):329-337. DOI: 10.1038/gim.2013.143Glidewell J, Reefuis J, Rasmu ssen SA, et al. Factors affecting maternal participation in the genetic component of the National Birth Defects Prevention Study — United States, 1997-2007. Genet Med. 2014;16(4):329-337. DOI: 10.1038/gim.2013.143Dempfle A, Scherag A, Hein R, et al. Gene-environment interactions for complex traits: defnitions, methodological requirements and challenges. Eur J Hum Genet. 2008;16(10):1164-1172. DOI: 10.1038/ejhg.2008.106Dempfle A, Scherag A, Hein R, et al. Gene-environment interactions for complex traits: defnitions, methodological requirements and challenges. Eur J Hum Genet. 2008;16(10):1164-1172. DOI: 10.1038/ejhg.2008.106Burton PR, Hansell AL, Fortier I, et al. Size matters: just how big is BIG?: Quantifying realistic sample size requirements for human genome epidemiology. Int J Epidemiol. 2009;38(1):263-273. DOI: 10.1093/ije/dyn147Burton PR, Hansell AL, Fortier I, et al. Size matters: just how big is BIG?: Quantifying realistic sample size requirements for human genome epidemiology. Int J Epidemiol. 2009;38(1):263-273. DOI: 10.1093/ije/dyn147Galea S. An argument for a consequentialist epidemiology. Am J Epidemiol. 2013;178(8):1185-1191. DOI: 10.1093/aje/kwt172Galea S. An argument for a consequentialist epidemiology. Am J Epidemiol. 2013;178(8):1185-1191. DOI: 10.1093/aje/kwt172Horgan RP, Clancy OH, Myers JE, Baker PN. An overview of proteomic and metabolomic technologies and their application to pregnancy research. BJOG. 2009;116(2):173-181. DOI: 10.1111/j.1471-0528.2008.01997.xHorgan RP, Clancy OH, Myers JE, Baker PN. An overview of proteomic and metabolomic technologies and their application to pregnancy research. BJOG. 2009;116(2):173-181. DOI: 10.1111/j.1471-0528.2008.01997.xMitchell AA, Gilboa SM, Werler MM, et al. Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. Am J Obstet Gynecol. 2011;205(1):51.e1-51.e8. DOI: 10.1016/j.ajog.2011.02.029Mitchell AA, Gilboa SM, Werler MM, et al. Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. Am J Obstet Gynecol. 2011;205(1):51.e1-51.e8. DOI: 10.1016/j.ajog.2011.02.029Correa A, Marcinkevage J. Pregnancy obesity and the risk of birth defects: an update. Nutr Rev. 2013;71(Suppl 1):S68—S77. DOI: 10.1111/nure.12058Correa A, Marcinkevage J. Pregnancy obesity and the risk of birth defects: an update. Nutr Rev. 2013;71(Suppl 1):S68—S77. DOI: 10.1111/nure.12058Davies MJ, Moore VM, Willson KJ, et al. Reproductive technologies and the risk of birth defects. N Engl J Med. 2012;366(19):1803-1813. DOI: 10.1056/NEJMoa1008095Davies MJ, Moore VM, Willson KJ, et al. Reproductive technologies and the risk of birth defects. N Engl J Med. 2012;366(19):1803-1813. DOI: 10.1056/NEJMoa1008095Okun N, Sierra S. Pregnancy outcomes afer assisted human reproduction. J Obstet Gynaecol Can. 2014;36(1):64-83. DOI: 10.1016/S1701-2163(15)30685-XOkun N, Sierra S. Pregnancy outcomes afer assisted human reproduction. J Obstet Gynaecol Can. 2014;36(1):64-83. DOI: 10.1016/S1701-2163(15)30685-XAlwan S, Chambers CD. Findings from the National Birth Defects Prevention Study: interpretation and translation for the clinician. Birth Defects Res A Clin Mol Teratol. 2015;103(8):721-728. DOI: 10.1002/bdra.and23394Alwan S, Chambers CD. Findings from the National Birth Defects Prevention Study: interpretation and translation for the clinician. Birth Defects Res A Clin Mol Teratol. 2015;103(8):721-728. DOI: 10.1002/bdra.and23394Tinker SC, Devine O, Mai C, et al. Estimate of the potential impact of folic acid fortifcation of corn masa flour on the prevention of neural tube defects. Birth Defects Res A Clin Mol Teratol. 2013;97(10):649-657. DOI: 10.1002/bdra.23158Tinker SC, Devine O, Mai C, et al. Estimate of the potential impact of folic acid fortifcation of corn masa flour on the prevention of neural tube defects. Birth Defects Res A Clin Mol Teratol. 2013;97(10):649-657. DOI: 10.1002/bdra.23158Werler MM, Ahrens KA, Bosco JL, et al. Use of antiepileptic medications in pregnancy in relation to risks of birth defects. Ann Epidemiol. 2011;21(11):842-850. DOI: 10.1016/j.annepidem.2011.08.002Werler MM, Ahrens KA, Bosco JL, et al. Use of antiepileptic medications in pregnancy in relation to risks of birth defects. Ann Epidemiol. 2011;21(11):842-850. DOI: 10.1016/j.annepidem.2011.08.002Hernandez-Diaz S, Smith CR, Shen A, et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology. 2012;78(21):1692-1699. DOI: 10.1212/WNL.0b013e3182574f39Hernandez-Diaz S, Smith CR, Shen A, et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology. 2012;78(21):1692-1699. DOI: 10.1212/WNL.0b013e3182574f39Shinde MU, Vuong AM, Brender JD, et al. Prenatal exposure to nitrosatable drugs, vitamin C, and risk of selected birth defects. Birth Defects Res A Clin Mol Teratol. 2013;97(8):515-531. DOI: 10.1002/bdra.23137Shinde MU, Vuong AM, Brender JD, et al. Prenatal exposure to nitrosatable drugs, vitamin C, and risk of selected birth defects. Birth Defects Res A Clin Mol Teratol. 2013;97(8):515-531. DOI: 10.1002/bdra.23137Benedum CM, Yazdy MM, Mitchell AA, Werler MM. Impact of periconceptional use of nitrosatable drugs on the risk of neural tube defects. Am J Epidemiol. 2015; 182(8):675-684. DOI: 10.1093/aje/kwv126Benedum CM, Yazdy MM, Mitchell AA, Werler MM. Impact of periconceptional use of nitrosatable drugs on the risk of neural tube defects. Am J Epidemiol. 2015; 182(8):675-684. DOI: 10.1093/aje/kwv126Kim GW, Lin JE, Blomain ES, Waldman SA. Antiobesity pharmacotherapy: new drugs and emerging targets. Clin Pharmacol Ter. 2014;95(1):53-66. DOI: 10.1038/clpt.2013.204Kim GW, Lin JE, Blomain ES, Waldman SA. Antiobesity pharmacotherapy: new drugs and emerging targets. Clin Pharmacol Ter. 2014;95(1):53-66. DOI: 10.1038/clpt.2013.204Adam MP, Polifa JE, Friedman JM. Evolving knowledge of the teratogenicity of medications in human pregnancy. Am J Med Genet C Semin Med Genet. 2011;157C(3):175-182. DOI: 10.1002/ajmg.c.30313Adam MP, Polifa JE, Friedman JM. Evolving knowledge of the teratogenicity of medications in human pregnancy. Am J Med Genet C Semin Med Genet. 2011;157C(3):175-182. DOI: 10.1002/ajmg.c.30313Centers for Disease Control and Prevention (CDC). Smoking during pregnancy--United States, 1990-2002. MMWR Morb Mortal Wkly Rep. 2004;53(39):911-915.Centers for Disease Control and Prevention (CDC). Smoking during pregnancy--United States, 1990-2002. MMWR Morb Mortal Wkly Rep. 2004;53(39):911-915.Tong VT, Dietz PM, Morrow B, et al. Trends in smoking before, during, and afer pregnancy — Pregnancy Risk Assessment Monitoring System, United States, 40 sites, 2000-2010. MMWR Surveill Summ. 2013;62(6):1-19.Tong VT, Dietz PM, Morrow B, et al. Trends in smoking before, during, and afer pregnancy — Pregnancy Risk Assessment Monitoring System, United States, 40 sites, 2000-2010. MMWR Surveill Summ. 2013;62(6):1-19.Mokdad AH, Serdula MK, Dietz WH, et al. Te spread of the obesity epidemic in the United States, 1991-1998. JAMA. 1999;282(16):1519-1522. DOI: 10.1001/jama.282.16.1519Mokdad AH, Serdula MK, Dietz WH, et al. Te spread of the obesity epidemic in the United States, 1991-1998. JAMA. 1999;282(16):1519-1522. DOI: 10.1001/jama.282.16.1519Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of obesity in the United States, 2009-2010. NCHS Data Brief. 2012;(82):1-8.Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of obesity in the United States, 2009-2010. NCHS Data Brief. 2012;(82):1-8.England LJ, Anderson BL, Tong VT, et al. Screening practices and attitudes of obstetricians-gynecologists toward new and emerging tobacco products. Am J Obstet Gynecol. 2014;211(6):695.e1-7. DOI: 10.1016/j.ajog.2014.05.041England LJ, Anderson BL, Tong VT, et al. Screening practices and attitudes of obstetricians-gynecologists toward new and emerging tobacco products. Am J Obstet Gynecol. 2014;211(6):695.e1-7. DOI: 10.1016/j.ajog.2014.05.041

The authors declare that there are no conflicts of interest present.